Ignacio
Bernabeu Morón
Universidad Autónoma de Madrid
Madrid, EspañaPublicacións en colaboración con investigadores/as de Universidad Autónoma de Madrid (15)
2024
-
Integrative clinical, hormonal, and molecular data associate with invasiveness in acromegaly: REMAH study
European Journal of Endocrinology, Vol. 190, Núm. 6, pp. 421-433
2023
-
Mortality in Acromegaly Diagnosed in Older Individuals in Spain Is Higher in Women Compared to the General Spanish Population
The Journal of clinical endocrinology and metabolism, Vol. 108, Núm. 9, pp. 2193-2202
2022
-
Data mining analyses for precision medicine in acromegaly: a proof of concept
Scientific Reports, Vol. 12, Núm. 1
-
Factors associated with therapeutic response in acromegaly diagnosed in the elderly in Spain
Frontiers in Endocrinology, Vol. 13
-
Implications of Heterogeneity of Epithelial-Mesenchymal States in Acromegaly Therapeutic Pharmacologic Response
Biomedicines, Vol. 10, Núm. 2
2021
-
Craniopharyngioma in the Elderly: A Multicenter and Nationwide Study in Spain
Neuroendocrinology, Vol. 111, Núm. 10, pp. 925-936
-
Molecular determinants of enhanced response to somatostatin receptor ligands after debulking in large GH-producing adenomas
Clinical Endocrinology, Vol. 94, Núm. 5, pp. 811-819
2020
-
Molecular profiling for acromegaly treatment: a validation study
Endocrine-related cancer, Vol. 27, Núm. 6, pp. 375-389
2016
-
Long-term treatment with pegvisomant for acromegaly: A 10-year experience
Clinical Endocrinology, Vol. 84, Núm. 4, pp. 540-550
-
Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY
Pituitary, Vol. 19, Núm. 2, pp. 127-137
2015
-
Analysis of IGF(CA)19 and IGFBP3-202A/C gene polymorphisms in patients with acromegaly: Association with clinical presentation and response to treatments
European Journal of Endocrinology, Vol. 172, Núm. 2, pp. 115-122
2013
-
Pegvisomant and cabergoline combination therapy in acromegaly
Pituitary, Vol. 16, Núm. 1, pp. 101-108
2011
-
Somatotroph tumor progression during pegvisomant therapy: A clinical and molecular study
Journal of Clinical Endocrinology and Metabolism, Vol. 96, Núm. 2
2010
-
Pegvisomant-induced liver injury is related to the UGT1A1*28 polymorphism of Gilbert's syndrome
Journal of Clinical Endocrinology and Metabolism, Vol. 95, Núm. 5, pp. 2147-2154
-
The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly
Journal of Clinical Endocrinology and Metabolism, Vol. 95, Núm. 1, pp. 222-229